40 matching use cases
Federal Government ×HHS/FDA/CDER ×Unassigned ×
OMB-IND-ROW814OMB Individually Reported

Renamed: 356H Machine Learning (ML) Facility Supply Chain Role Classification Previously: 356H ML Facility Supply Chain Role Classification

Manual classification of facility supply chain roles from FDA industry submissions (356h forms) is time-consuming and inefficient

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW815OMB Individually Reported

Renamed: Risk-based FAR Review & Decision Support Previously: Field Alert Reports (FAR) Prioritization Model

Manual and subjective assessment process for Field Alert Reports (FARs) can lead to inconsistency in prioritizing and assessing reports, potentially leading to ineffective resourc…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW816OMB Individually Reported

Analytics-Driven Supplement Evaluation (ASE)

Exponential increase in post-approval chemistry, manufacturing, and controls (CMC) change submissions, with 80% being Changes Being Effected (CBE-30/0) notifications that may be s…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW817OMB Individually Reported

Renamed: FAR-based Facility Signal Detection Tool Previously: Post-market Surveillance Reports Signal Detection and Cluster Analysis.

Need for proactive detection of quality signals in post-market surveillance reports using statistical process control and topic modeling to identify potential drug quality hazards…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW818OMB Individually Reported

MedWatch Dashboard

Need to proactively identify emerging issues and clusters within MedWatch reports using advanced analytics.

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW819OMB Individually Reported

Quality Surveillance Dashboard (QSD)

Need for consistent, data-driven assessment of drug manufacturing facilities and proactive detection of potential quality signals that could indicate problems with drug safety or…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW820OMB Individually Reported

Annual Report CMC

FDA receives numerous annual reports from drug manufacturers containing important manufacturing and quality information, but key details can be difficult to locate quickly within…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW821OMB Individually Reported

Renamed: Application References Previously: Application-DMF Reference

FDA receives extensive drug application submissions that contain valuable references to related applications, but these relationships aren't always captured in existing regulatory…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW822OMB Individually Reported

Renamed: Extracting DMF Facilities from unstructured documents Previously: DMF (Drug Master File) Facilities

FDA receives Drug Master File (DMF) submissions containing valuable information about manufacturing facilities, but this data exists in various document formats that require manua…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW823OMB Individually Reported

Renamed: Information Visualization Platform (InfoViP) to Support Analysis of FAERS safety reports Previously: Information Visualization Platform (InfoViP) to Support Analysis of adverse event reports

The AI is intended to support the analysis of FAERS Individual Case Study Reports in post-market safety surveillance by automating duplicate detection, creating temporal visualiza…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW825OMB Individually Reported

Renamed: Module 3 Facilities Extraction Previously: Module 3 Faculties

FDA receives drug application submissions (ANDA, NDA, BLA) that contain important manufacturing facility information in Module 3 documents, but this data requires manual review to…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW826OMB Individually Reported

Packaging Materials and Suppliers

FDA needs to efficiently identify which Drug Master Files (DMFs) contain specific packaging materials and understand how these materials connect to drug applications, but this inf…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW828OMB Individually Reported

Real World Data/Evidence

FDA receives numerous submissions containing real-world data and evidence, but identifying and cataloging these studies across various submission types is time-intensive and criti…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW829OMB Individually Reported

Regulatory Starting Material

FDA needs comprehensive visibility into the upstream supply chain for drug manufacturing, particularly tracking regulatory starting materials and their suppliers across approved a…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW830OMB Individually Reported

Resource Capacity Planning

FDA needs to accurately predict the volume and complexity of incoming drug application submissions to ensure appropriate staffing and resources are available for timely reviews un…

OMB Individually ReportedOtherLow risk
OMB-IND-ROW834OMB Individually Reported

CDER Publications

Inefficient manual curation and categorization of publications by CDER authors. It aims to automate the process of organizing publications by focus areas for data call responses a…

OMB Individually ReportedScienceLow risk
OMB-IND-ROW835OMB Individually Reported

CDER Regulatory Science Research (RSR) Projects AI for Process Control in Advanced Manufacturing

Need for better process control in continuous manufacturing and development of soft sensors for real-time release testing strategies.

OMB Individually ReportedScienceMedium risk
OMB-IND-ROW836OMB Individually Reported

Creating a development network

The AI is intended to solve the problem of inconsistent data formats and inefficient access to unstructured clinical data across multiple healthcare sites. It aims to standardize…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW837OMB Individually Reported

Developing an Objective and Quantitative Endpoint for Atopic Dermatitis in Pediatric and Adult Populations

Intended to solve the problem of lacking objective, quantitative methods to assess nocturnal scratching in children with atopic dermatitis. It aims to create a digital endpoint th…

OMB Individually ReportedHealth and MedicalMedium risk
OMB-IND-ROW838OMB Individually Reported

Drug Shortage Predictive Model

Drug shortages have increased significantly since 2017 and worsened during COVID-19, creating critical gaps in patient access to essential medications. FDA seeks to develop predic…

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW839OMB Individually Reported

Category Subcategory Classification - Safety Reports Bot

Manual analysis and data entry of safety report submissions is time-intensive and requires staff to review scanned PDFs and determine appropriate categories.

OMB Individually ReportedHealth and MedicalLow risk
OMB-IND-ROW840OMB Individually Reported

Data Extraction from IND Safety Reports using OCR/AI Technologies

Manual extraction of data from IND safety reports is labor-intensive and time-consuming for regulatory staff.

OMB Individually ReportedInformation TechnologyLow risk
OMB-IND-ROW841OMB Individually Reported

AI Editing Tool

This AI model is designed to detect style and formatting inconsistencies in FDA draft documents by comparing them against the FDA CDER Style Guide standards. It solves the problem…

OMB Individually ReportedAdministrative FunctionsLow risk
OMB-IND-ROW842OMB Individually Reported

Use case package 1: Empirical application of the Sentinel EHR and claims Data Partner network to address ARIA insufficient inferential requests (UC1)

This AI project is designed to solve the problem of determining whether available data sources and analytical methods are suitable for specific pharmacoepidemiologic research ques…

OMB Individually ReportedHealth and MedicalLow risk